You are here: Home » News-CM » Companies » News
Business Standard

Glenmark Pharmaceuticals to initiate clinical study of GBR 1342

Capital Market 

Its second oncology candidate to enter clinical trials

Glenmark Pharmaceuticals announced that the USFDA cleared the company's Investigational New Drug (IND) application to initiate a Phase 1 study of GBR 1342, a humanized, bispecific monoclonal antibody (bsAb) being studied for the treatment of multiple myeloma in patients who have received prior therapies. GBR 1342 is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors. It is based on Glenmark's proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, May 16 2017. 09:55 IST